Assessment of biomarkers associated with renal decline for prediction of incident distal sensory polyneuropathy in type 2 diabetes

Kirsten Peters; Timothy M. E. Davis; Isabella A. Joubert; Martin K. Mead; Angelo Bautista; Wendy A. Davis

doi:10.1038/s41598-025-24110-8

Back

Assessment of biomarkers associated with renal decline for prediction of incident distal sensory polyneuropathy in type 2 diabetes

Journal article

Open access

Peer reviewed

Assessment of biomarkers associated with renal decline for prediction of incident distal sensory polyneuropathy in type 2 diabetes

Kirsten Peters, Timothy M. E. Davis, Isabella A. Joubert, Martin K. Mead, Angelo Bautista and Wendy A. Davis

Scientific reports, Vol.15(1), 40214

2025

DOI: https://doi.org/10.1038/s41598-025-24110-8

PMID: 41249435

Files and links (1)

pdf

Published1.27 MBDownload View

Published (Version of Record) Open Access CC BY-NC-ND V4.0

Abstract

The PromarkerD test accurately predicts diabetic kidney disease. We aimed to determine whether PromarkerD and/or its constituent biomarkers would also identify an increased risk of distal sensory polyneuropathy (DSPN) complicating type 2 diabetes (T2D). We selected 160 community-based adults without baseline DSPN (mean age 69 years, 56% males), 80 of whom were free of DSPN after four years and 80 who developed DSN based on the vibration perception threshold. Baseline plasma apolipoprotein A-IV (ApoA4), CD5 antigen-like protein (CD5L) and insulin-like growth factor binding protein 3 (IBP3) concentrations were measured and PromarkerD risk scores were generated. Logistic regression modelling assessed associations between PromarkerD risk and its component proteins and incident DSPN. At Year 4, 77 of 151 with valid data (51%) had developed DSPN. The PromarkerD area under the receiver operating characteristic curve was 0.53 (95% CI 0.43-0.62). The odds ratio for the PromarkerD score for identifying incident DSPN was 0.97 (95% CI 0.82-1.16, P = 0.76), with similar non-significant results for plasma ApoA4, CD5L, and IBP3. PromarkerD and its constituent protein concentrations, each with some preclinical or epidemiological evidence of an association with DSPN, did not predict incident DSPN over 4 years of follow-up. These data support microangiopathy-specific pathophysiological mechanisms in T2D.

Details

Title: Assessment of biomarkers associated with renal decline for prediction of incident distal sensory polyneuropathy in type 2 diabetes
Authors/Creators: Kirsten Peters - Prote Int, Perth, WA, Australia
Timothy M. E. Davis - The University of Melbourne
Isabella A. Joubert - Prote Int, Perth, WA, Australia
Martin K. Mead - Prote Int, Perth, WA, Australia
Angelo Bautista - Prote Int, Perth, WA, Australia
Wendy A. Davis - The University of Melbourne
Publication Details: Scientific reports, Vol.15(1), 40214
Publisher: NATURE PORTFOLIO
Number of pages: 6
Grant note: Australian Centre for Accelerating Diabetes Innovations 513781 and 1042231 / National Health and Medical Research Council; National Health & Medical Research Council (NHMRC) of Australia
Identifiers: 991005884846907891
Murdoch Affiliation: School of Medical, Molecular and Forensic Sciences
Language: English
Resource Type: Journal article

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: SDGs in the Output

Metrics

1 Record Views